Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Without a referral, your visit may not be authorized under TRICARE Prime
Net income rose to $11.1 million and adjusted EBITDA rose to $32.3 million
This multicenter, double-blind, placebo-controlled Phase 2 RCT (NCT05377580) enrolled 150 Chinese patients who were randomized to receive various doses of Picankibart through intravenous injection during the induction period (Period 1) followed by subcutaneous maintenance therapy (Period 2), with quadruple masking involving participants, care providers, investigators, and outcomes assessors
As a result lower energy levels and frequent inflammation often occur which opens the door to diseases and accelerates the ageing process
US$ 28.91
US$ 27.19
US$ 29.32
US$ 28.67
